Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP).
Sina M Hopff, Katharina S Appel, Olga Miljukov, Johannes Schneider, Marylyn M Addo, Robert Bals, Sven Bercker, Sabine Blaschke, Isabel Bröhl, Nikolaus Büchner, Hiwa Dashti, Johanna Erber, Anette Friedrichs, Ramsia Geisler, Siri Göpel, Marina Hagen, Frank Hanses, Björn-Erik Ole Jensen, Maria Keul, Adalbert Krawczyk, Bettina Lorenz-Depiereux, Patrick Meybohm, Milena Milovanovic, Lazar Mitrov, Carolin Nürnberger, Wilfried Obst, Christoph Römmele, Christian Schäfer, Christian Scheer, Margarete Scherer, Julia Schmidt, Kristina Seibel, Shimita Sikdar, Johannes Josef Tebbe, Phil-Robin Tepasse, Philipp Thelen, Maria J G T Vehreschild, Christina Weismantel, J Janne Vehreschild
{"title":"Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP).","authors":"Sina M Hopff, Katharina S Appel, Olga Miljukov, Johannes Schneider, Marylyn M Addo, Robert Bals, Sven Bercker, Sabine Blaschke, Isabel Bröhl, Nikolaus Büchner, Hiwa Dashti, Johanna Erber, Anette Friedrichs, Ramsia Geisler, Siri Göpel, Marina Hagen, Frank Hanses, Björn-Erik Ole Jensen, Maria Keul, Adalbert Krawczyk, Bettina Lorenz-Depiereux, Patrick Meybohm, Milena Milovanovic, Lazar Mitrov, Carolin Nürnberger, Wilfried Obst, Christoph Römmele, Christian Schäfer, Christian Scheer, Margarete Scherer, Julia Schmidt, Kristina Seibel, Shimita Sikdar, Johannes Josef Tebbe, Phil-Robin Tepasse, Philipp Thelen, Maria J G T Vehreschild, Christina Weismantel, J Janne Vehreschild","doi":"10.1007/s15010-024-02270-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The influence of new SARS-CoV-2 variants on the post-COVID-19 condition (PCC) remains unanswered. Therefore, we examined the prevalence and predictors of PCC-related symptoms in patients infected with the SARS-CoV-2 variants delta or omicron.</p><p><strong>Methods: </strong>We compared prevalences and risk factors of acute and PCC-related symptoms three months after primary infection (3MFU) between delta- and omicron-infected patients from the Cross-Sectoral Platform of the German National Pandemic Cohort Network. Health-related quality of life (HrQoL) was determined by the EQ-5D-5L index score and trend groups were calculated to describe changes of HrQoL between different time points.</p><p><strong>Results: </strong>We considered 758 patients for our analysis (delta: n = 341; omicron: n = 417). Compared with omicron patients, delta patients had a similar prevalence of PCC at the 3MFU (p = 0.354), whereby fatigue occurred most frequently (n = 256, 34%). HrQoL was comparable between the groups with the lowest EQ-5D-5L index score (0.75, 95% CI 0.73-0.78) at disease onset. While most patients (69%, n = 348) never showed a declined HrQoL, it deteriorated substantially in 37 patients (7%) from the acute phase to the 3MFU of which 27 were infected with omicron.</p><p><strong>Conclusion: </strong>With quality-controlled data from a multicenter cohort, we showed that PCC is an equally common challenge for patients infected with the SARS-CoV-2 variants delta and omicron at least for the German population. Developing the EQ-5D-5L index score trend groups showed that over two thirds of patients did not experience any restrictions in their HrQoL due to or after the SARS-CoV-2 infection at the 3MFU.</p><p><strong>Clinical trail registration: </strong>The cohort is registered at ClinicalTrials.gov since February 24, 2021 (Identifier: NCT04768998).</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":"2253-2267"},"PeriodicalIF":5.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621170/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s15010-024-02270-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The influence of new SARS-CoV-2 variants on the post-COVID-19 condition (PCC) remains unanswered. Therefore, we examined the prevalence and predictors of PCC-related symptoms in patients infected with the SARS-CoV-2 variants delta or omicron.
Methods: We compared prevalences and risk factors of acute and PCC-related symptoms three months after primary infection (3MFU) between delta- and omicron-infected patients from the Cross-Sectoral Platform of the German National Pandemic Cohort Network. Health-related quality of life (HrQoL) was determined by the EQ-5D-5L index score and trend groups were calculated to describe changes of HrQoL between different time points.
Results: We considered 758 patients for our analysis (delta: n = 341; omicron: n = 417). Compared with omicron patients, delta patients had a similar prevalence of PCC at the 3MFU (p = 0.354), whereby fatigue occurred most frequently (n = 256, 34%). HrQoL was comparable between the groups with the lowest EQ-5D-5L index score (0.75, 95% CI 0.73-0.78) at disease onset. While most patients (69%, n = 348) never showed a declined HrQoL, it deteriorated substantially in 37 patients (7%) from the acute phase to the 3MFU of which 27 were infected with omicron.
Conclusion: With quality-controlled data from a multicenter cohort, we showed that PCC is an equally common challenge for patients infected with the SARS-CoV-2 variants delta and omicron at least for the German population. Developing the EQ-5D-5L index score trend groups showed that over two thirds of patients did not experience any restrictions in their HrQoL due to or after the SARS-CoV-2 infection at the 3MFU.
Clinical trail registration: The cohort is registered at ClinicalTrials.gov since February 24, 2021 (Identifier: NCT04768998).
期刊介绍：
Infection is a journal dedicated to serving as a global forum for the presentation and discussion of clinically relevant information on infectious diseases. Its primary goal is to engage readers and contributors from various regions around the world in the exchange of knowledge about the etiology, pathogenesis, diagnosis, and treatment of infectious diseases, both in outpatient and inpatient settings.
The journal covers a wide range of topics, including:
Etiology: The study of the causes of infectious diseases.
Pathogenesis: The process by which an infectious agent causes disease.
Diagnosis: The methods and techniques used to identify infectious diseases.
Treatment: The medical interventions and strategies employed to treat infectious diseases.
Public Health: Issues of local, regional, or international significance related to infectious diseases, including prevention, control, and management strategies.
Hospital Epidemiology: The study of the spread of infectious diseases within healthcare settings and the measures to prevent nosocomial infections.
In addition to these, Infection also includes a specialized "Images" section, which focuses on high-quality visual content, such as images, photographs, and microscopic slides, accompanied by brief abstracts. This section is designed to highlight the clinical and diagnostic value of visual aids in the field of infectious diseases, as many conditions present with characteristic clinical signs that can be diagnosed through inspection, and imaging and microscopy are crucial for accurate diagnosis. The journal's comprehensive approach ensures that it remains a valuable resource for healthcare professionals and researchers in the field of infectious diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
